$3.97 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$15.88 - $54.21The lowest and highst price in the last 52 weeks.
0.0xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$0.00 (0.0%)Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
|Market Cap||$3.97 Billion|
|Dividend Yield||$0.00 (0.0%)|
|1 Year Return||-23.2%|
|Outstanding Shares||155 Million|
|Avg 30 Day Volume||1.45 Million|
|Earnings per Share||$0.00|
|Price to Sales Ratio||-|
|Price to Book Ratio||-|
|Revenue to Enterprise Value||-|
|EBIT to Enterprise Value||-|
|Total Debt to Enterprise Value||-|
|Debt to Equity||-|
|Quarterly Earnings Growth (YoY)||-|
|Return on Equity||-|
|Return on Assets||-|
|Return on Invested Capital||-|
SAN CARLOS, Calif., July 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will rep...Intrado Digital Media, 2 months ago
An investigation on behalf of investors in Iovance Biotherapeutics, Inc. (NASDSQ:IOVA) shares over potential wrongdoing at Iovance Biotherapeutics, Inc. was announced. San Diego, CA -- ( SBWIRE ) -...SBWire, 3 months ago
SAN CARLOS, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, announce...Intrado Digital Media, 3 months ago